Prostatype Genomics AB (publ)
PROGEN
Rank in Stocks
#33659
Prostatype Genomics AB focuses on creating, marketing, and selling... Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Share Price
$0.01025363
Last synced: 2026-11-09
Market Cap
$338.37K
Change (1 day)
2.86%
Change (1 year)
-84.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Prostatype Genomics AB (publ) (PROGEN)
Category
Healthcare
EPS for Prostatype Genomics AB (publ) (PROGEN)
EPS as of June 2026 TTM: $-0.06
According to Prostatype Genomics AB (publ)'s latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2025 the company had an EPS of $-0.14, an increase over its 2024 EPS of $-1.24.
EPS history for Prostatype Genomics AB (publ) from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | -60.36% |
| 2025 | $-0.14 | -88.45% |
| 2024 | $-1.24 | 3.85% |
| 2023 | $-1.19 | -1.15% |
| 2022 | $-1.21 | 2.70% |
| 2021 | $-1.18 | -61.38% |
| 2020 | $-3.04 | -95.39% |
| 2019 | $-66.00 | 484.36% |
| 2018 | $-11.29 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $18.99 | -34,316.22% |
US
|
|
| $6.12 | -11,127.03% |
US
|
|
| $1.38 | -2,581.26% |
CN
|
|
| $14.83 | -26,820.72% |
US
|
|
| $5.09 | -9,271.17% |
US
|
Questions about Prostatype Genomics AB (publ)'s earnings per share (EPS)
What is Prostatype Genomics AB (publ)'s earnings per share (EPS)?
Prostatype Genomics AB (publ)'s earnings per share (EPS) over the last twelve months is $-0.06, as of Jun 2026.
What was Prostatype Genomics AB (publ)'s earnings per share (EPS) in 2025?
In 2025, Prostatype Genomics AB (publ)'s earnings per share (EPS) was $-0.14, compared with $-1.24 in 2024.
How has Prostatype Genomics AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Prostatype Genomics AB (publ)'s earnings per share (EPS) was highest in 2025 ($-0.14) and lowest in 2020 ($-3.04).
How does Prostatype Genomics AB (publ)'s earnings per share (EPS) compare with similar companies?
Prostatype Genomics AB (publ)'s earnings per share (EPS) ($-0.06) is lower than that of all 5 similar companies listed above. The highest among them is Thermo Fisher Scientific Inc., with $18.99.